|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
101,390,000 |
Market
Cap: |
1.63(B) |
Last
Volume: |
668,805 |
Avg
Vol: |
666,964 |
52
Week Range: |
$12.32 - $16.78 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
215,000 |
664,000 |
Total Buy Value |
$0 |
$0 |
$2,804,388 |
$8,468,005 |
Total People Bought |
0 |
0 |
1 |
2 |
Total Buy Transactions |
0 |
0 |
5 |
12 |
Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Haimovitz Jules |
Director |
|
2018-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,517 |
22,717 |
|
- |
|
Bickerstaff George |
Director |
|
2017-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
14,513 |
14,513 |
|
- |
|
Kostas Odysseas D |
Director |
|
2017-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
14,513 |
14,513 |
|
- |
|
Aguiar Michael W |
President & Chief Exec Officer |
|
2017-12-04 |
4 |
S |
$13.13 |
$157,791 |
D/D |
(12,022) |
980,907 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-11-21 |
4 |
AS |
$13.31 |
$179,171 |
D/D |
(13,460) |
321,742 |
|
- |
|
Abercrombie George B |
Sr. VP & Chief Comm. Officer |
|
2017-11-21 |
4 |
AS |
$13.26 |
$69,145 |
D/D |
(5,215) |
258,651 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2017-11-21 |
4 |
AS |
$13.29 |
$172,795 |
D/D |
(13,000) |
213,800 |
|
- |
|
Faerm Michael E. |
Sr VP & Chief Business Officer |
|
2017-11-20 |
4 |
D |
$13.17 |
$58,870 |
D/D |
(4,470) |
279,422 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-11-20 |
4 |
AS |
$13.04 |
$23,798 |
D/D |
(1,825) |
335,202 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-11-20 |
4 |
D |
$13.17 |
$80,877 |
D/D |
(6,141) |
337,027 |
|
- |
|
Abercrombie George B |
Sr. VP & Chief Comm. Officer |
|
2017-11-20 |
4 |
D |
$13.17 |
$44,225 |
D/D |
(3,358) |
263,866 |
|
- |
|
Aguiar Michael W |
President & Chief Exec Officer |
|
2017-11-20 |
4 |
D |
$13.17 |
$566,810 |
D/D |
(43,038) |
992,929 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2017-11-20 |
4 |
D |
$13.17 |
$194,350 |
D/D |
(14,757) |
226,800 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-08-21 |
4 |
AS |
$12.20 |
$22,265 |
D/D |
(1,825) |
343,168 |
|
- |
|
Faerm Michael E. |
Sr VP & Chief Business Officer |
|
2017-08-20 |
4 |
D |
$12.28 |
$39,038 |
D/D |
(3,179) |
283,892 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-08-20 |
4 |
D |
$12.28 |
$70,856 |
D/D |
(5,770) |
344,993 |
|
- |
|
Aguiar Michael W |
President & Chief Exec Officer |
|
2017-08-20 |
4 |
D |
$12.28 |
$158,621 |
D/D |
(12,917) |
1,035,967 |
|
- |
|
Abercrombie George B |
Sr. VP & Chief Comm. Officer |
|
2017-08-20 |
4 |
D |
$12.28 |
$35,440 |
D/D |
(2,886) |
267,224 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2017-08-20 |
4 |
D |
$12.28 |
$31,879 |
D/D |
(2,596) |
241,557 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2017-05-22 |
4 |
S |
$12.01 |
$93,858 |
D/D |
(7,815) |
244,153 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-05-22 |
4 |
AS |
$11.85 |
$21,626 |
D/D |
(1,825) |
350,763 |
|
- |
|
Abercrombie George B |
Sr. VP & Chief Comm. Officer |
|
2017-05-20 |
4 |
D |
$11.86 |
$26,424 |
D/D |
(2,228) |
270,110 |
|
- |
|
Witek Theodore L Jr |
Sr. VP & Chief Scientific Off. |
|
2017-05-20 |
4 |
D |
$11.86 |
$30,717 |
D/D |
(2,590) |
251,968 |
|
- |
|
Desparbes Eric |
SVP and CFO |
|
2017-05-20 |
4 |
D |
$11.86 |
$49,907 |
D/D |
(4,208) |
352,588 |
|
- |
|
Faerm Michael E. |
Sr VP & Chief Business Officer |
|
2017-05-20 |
4 |
D |
$11.86 |
$37,667 |
D/D |
(3,176) |
287,071 |
|
- |
|
704 Records found
|
|
Page 6 of 29 |
|
|